Tags

Type your tag names separated by a space and hit enter

Ticagrelor Versus Clopidogrel in Patients with Late or Very Late Stent Thrombosis.
Cardiovasc Drugs Ther. 2020 Jun 22 [Online ahead of print]CD

Abstract

PURPOSE

To compare the effect of ticagrelor with clopidogrel in reducing the risk of ischemic cardiovascular events in patients with late or very late stent thrombosis (LST/VLST) after primary percutaneous coronary intervention (PCI).

METHODS

A total of 4538 patients with acute coronary syndrome were screened for angiographically determined LST/VLST. Two hundred and forty-one patients were included in the analysis and grouped according to ticagrelor (n = 81) or clopidogrel (n = 160) at discharge. The clinical outcome was major adverse cardiovascular events (MACE) defined as death, myocardial infarction (MI), ischemic stroke, and revascularization during the 1-yr follow-up period.

RESULTS

After propensity score matching, 65 pairs were generated. The incidence of MACE was significantly lower in the ticagrelor group compared with the clopidogrel group (9.3% vs. 21.5%, log-rank p = 0.048). However, no difference was observed in event rates of death, MI, ischemic stroke, and revascularization between the ticagrelor group and the clopidogrel group.

CONCLUSION

Following successful primary PCI, patients with LST/VLST who received ticagrelor had fewer ischemic cardiovascular events at 1-yr follow-up, compared with those who received clopidogrel.

Authors+Show Affiliations

Department of Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Department of Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Xiamen Cardiovascular Hospital, Xiamen University, Fujian, China.Department of Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Department of Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Department of Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Department of Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Department of Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Department of Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Department of Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Department of Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. hbyanfuwai2018@163.com. Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, China. hbyanfuwai2018@163.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32572652

Citation

Zhou, Jinying, et al. "Ticagrelor Versus Clopidogrel in Patients With Late or Very Late Stent Thrombosis." Cardiovascular Drugs and Therapy, 2020.
Zhou J, Tan Y, Liu C, et al. Ticagrelor Versus Clopidogrel in Patients with Late or Very Late Stent Thrombosis. Cardiovasc Drugs Ther. 2020.
Zhou, J., Tan, Y., Liu, C., Zhou, P., Sheng, Z., Li, J., Chen, R., Zhao, H., Song, L., & Yan, H. (2020). Ticagrelor Versus Clopidogrel in Patients with Late or Very Late Stent Thrombosis. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-020-07021-w
Zhou J, et al. Ticagrelor Versus Clopidogrel in Patients With Late or Very Late Stent Thrombosis. Cardiovasc Drugs Ther. 2020 Jun 22; PubMed PMID: 32572652.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ticagrelor Versus Clopidogrel in Patients with Late or Very Late Stent Thrombosis. AU - Zhou,Jinying, AU - Tan,Yu, AU - Liu,Chen, AU - Zhou,Peng, AU - Sheng,Zhaoxue, AU - Li,Jiannan, AU - Chen,Runzhen, AU - Zhao,Hanjun, AU - Song,Li, AU - Yan,Hongbing, Y1 - 2020/06/22/ PY - 2020/06/02/accepted PY - 2020/6/24/entrez KW - Antiplatelet therapy KW - Clopidogrel KW - Stent thrombosis KW - Ticagrelor JF - Cardiovascular drugs and therapy JO - Cardiovasc Drugs Ther N2 - PURPOSE: To compare the effect of ticagrelor with clopidogrel in reducing the risk of ischemic cardiovascular events in patients with late or very late stent thrombosis (LST/VLST) after primary percutaneous coronary intervention (PCI). METHODS: A total of 4538 patients with acute coronary syndrome were screened for angiographically determined LST/VLST. Two hundred and forty-one patients were included in the analysis and grouped according to ticagrelor (n = 81) or clopidogrel (n = 160) at discharge. The clinical outcome was major adverse cardiovascular events (MACE) defined as death, myocardial infarction (MI), ischemic stroke, and revascularization during the 1-yr follow-up period. RESULTS: After propensity score matching, 65 pairs were generated. The incidence of MACE was significantly lower in the ticagrelor group compared with the clopidogrel group (9.3% vs. 21.5%, log-rank p = 0.048). However, no difference was observed in event rates of death, MI, ischemic stroke, and revascularization between the ticagrelor group and the clopidogrel group. CONCLUSION: Following successful primary PCI, patients with LST/VLST who received ticagrelor had fewer ischemic cardiovascular events at 1-yr follow-up, compared with those who received clopidogrel. SN - 1573-7241 UR - https://www.unboundmedicine.com/medline/citation/32572652/Ticagrelor_Versus_Clopidogrel_in_Patients_with_Late_or_Very_Late_Stent_Thrombosis L2 - https://doi.org/10.1007/s10557-020-07021-w DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.